ClinicalTrials.gg
RecruitingNCT07500181Updated Sep 14, 2026

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

A Phase 1 interventional study of BAL2420 or placebo and BAL2420 or placebo in Healthy, sponsored by Basilea Pharmaceutica. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

BAL2420 (also known as BAL0302420) is being developed as an antibacterial agent for the treatment of severe infections caused by Gram-negative bacteria. In this study, the sponsor aims to investigate the safety, tolerability and pharmacokinetics (PK) of BAL2420 following administration of single ascending doses (Part A) and multiple ascending doses (Parts B and C) in healthy adult volunteers. In all parts of the study, in each cohort, a different dose of study drug is to be investigated against a matched placebo in a randomized and double-blind manner.

02

Conditions studied

  • Healthy

Keywords

  • BAL2420
  • BAL0302420
  • Antibacterial agent
  • Pharmacokinetics
  • Healthy adults
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : 18.0 to 30.0 kg/m2, inclusive, at screening
  • Total body weight: > 50 kg at screening

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled or active major systemic disease,
  • Active infection
  • Acute illness within 5 days prior to the first study drug administration that, in the opinion of the Investigator, may impact safety assessments.
  • Clinically-significant physical examination, vital signs, laboratory safety tests, or abnormalities
  • History of risk factors for or Torsades de Pointes
  • QTcF (Fridericia's corrected QT interval) > 450 msec (males) and > 470 msec (females) at screening.
  • Receipt of prescribed medication other than hormonal within the 30 days prior to admission to the clinical site.
  • Receipt of over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) within 14 days prior to admission to the clinical site.
  • History of relevant drug and/or food allergies, particularly to antibiotics.
  • History of tobacco use or e-cigarette within the past 6 months prior to the first study drug administration.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 12 months prior to screening.
  • Average intake of more than 24 units of alcohol per week: one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits.
  • Positive screen for surface antigen, hepatitis B core antibodies, virus antibodies, 1 and 2 antibodies, or syphilis at screening. Note: Hepatitis B vaccination is allowed.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Part A

    A single intravenous (IV) dose of BAL2420 or placebo will be administered to healthy subjects

    Drug: BAL2420 or placebo

  • Experimental
    Part B

    A daily IV dose of BAL2420 or placebo will be administered multiple times to healthy subjects

    Drug: BAL2420 or placebo

  • Experimental
    Part C

    A different IV dosing regimen of BAL2420 or placebo will be administered to healthy subjects

    Drug: BAL2420 or placebo

Interventions

  • DrugBAL2420 or placebo

    Single ascending dose administration (SAD)

  • DrugBAL2420 or placebo

    Multiple-ascending dose (MAD)

  • DrugBAL2420 or placebo

    MAD

06

What researchers measure

Primary outcomes

  1. Number of participants reporting adverse events (AEs) in Part A

    Time frame: From screening until Day 10

  2. Number of participants with abnormal electrocardiograms QT Interval in Part A

    Time frame: From screening until Day 10

  3. Number of participants reporting adverse events (AEs) in Part B and C

    Time frame: From screening until Day 14

  4. Number of participants with abnormal ECG QT Interval in Part B and C

    Time frame: From screening until Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 30, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07500181
Collaborators
German Federal Ministry of Education and Research, Italian Ministry of Economy and Finance, Health Emergency Preparedness and Response Authority, Novo Nordisk Foundation, Wellcome Trust 224842/Z/21/Z, Wellcome Trust 325026/Z/25/Z
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 4, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Thomas Kaindl, MD
Contact
thomas.kaindl@basilea.com
+41615671505
Thomas Kaindl, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion